Top

01-01-2015 | Osteoarthritis | Book Chapter | Article

13. Precision Medicine for Osteoarthritis

Authors: Christian J. H. Veillette, MD, MSc, FRCSC, Igor Jurisica, PhD

Publisher: Springer International Publishing

Abstract

Precision medicine, or what patients and the media often call personalized medicine, aims to utilize molecular profiles of patient biospecimens and increasingly precise outcome metrics from diverse biosensors to more accurately diagnose a disease, tailor the therapy a patient receives, and monitor response.

In order to accomplish the goals of precision medicine in osteoarthritis, several key components of biomedical research (target identification, marker identification, molecular mechanisms) and clinical medicine (treatment, diagnosis, health outcomes) must be seamlessly integrated across several data repositories (clinical records, biospecimen, -omics databases) and analyzed using integrative data mining and iterative learning strategies.

A clinically meaningful and feasible strategy is required for identifying OA phenotypes for targeted treatment.

The OA Data Integration Platform (OADIP) provides comprehensive, expert curated clinical and molecular data repository across OA. Advances in molecular profiling, interoperability, integration, and exchange of data combined with machine learning techniques will enable comprehensive signatures for OA subtypes to be identified and targeted for treatment and discovery.

The feasibility and reality of precision medicine for OA are on the horizon as we strive to provide the right care to the right patient at the right time.

Katsnelson A. Momentum grows to make “personalized” medicine more “precise”. Nat Med. 2013;19(3):249.CrossRefPubMed

National Research Council (US) Committee on a Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease [Internet]. Washington, DC: National Academies Press (US); 2011. http://www.ncbi.nlm.nih.gov/books/NBK91503/. Cited 6 Mar 2015.

Topol EJ. The creative destruction of medicine: how the digital revolution will create better health care. New York: Basic Books; 2012. 322 p.

Karsdal MA, Christiansen C, Ladel C, Henriksen K, Kraus VB, Bay-Jensen AC. Osteoarthritis–a case for personalized health care? Osteoarthr Cartil OARS Osteoarthr Res Soc. 2014;22(1):7–16.CrossRef

Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201–4.CrossRefPubMed

Baumann C, Rat A-C, Mainard D, Cuny C, Guillemin F. Importance of patient satisfaction with care in predicting osteoarthritis-specific health-related quality of life one year after total joint arthroplasty. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2011;20(10):1581–8.CrossRef

Becker R, Döring C, Denecke A, Brosz M. Expectation, satisfaction and clinical outcome of patients after total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc Off J ESSKA. 2011;19(9):1433–41.CrossRef

Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med. 2012;18(3):349–51.CrossRefPubMed

Zhu C-Q, Pintilie M, John T, Strumpf D, Shepherd FA, Der SD, et al. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer. 2009;10(5):331–40.CrossRefPubMed

10.

Sawitzke AD. Personalized medicine for osteoarthritis: where are we now? Ther Adv Musculoskelet Dis. 2013;5(2):67–75.PubMedCentralCrossRefPubMed

11.

Reynard LN, Loughlin J. Genetics and epigenetics of osteoarthritis. Maturitas. 2012;71(3):200–4.CrossRefPubMed

12.

Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115–26.CrossRefPubMed

13.

Carroll GJ, Breidahl WH, Jazayeri J. Confirmation of two major polyarticular osteoarthritis (POA) phenotypes–differentiation on the basis of joint topography. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2009;17(7):891–5.CrossRef

14.

Castañeda S, Roman-Blas JA, Largo R, Herrero-Beaumont G. Osteoarthritis: a progressive disease with changing phenotypes. Rheumatol Oxf Engl. 2014;53(1):1–3.CrossRef

15.

Herrero-Beaumont G, Roman-Blas JA, Castañeda S, Jimenez SA. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum. 2009;39(2):71–80.CrossRefPubMed

16.

Karsdal MA, Bihlet A, Byrjalsen I, Alexandersen P, Ladel C, Michaels M, et al. OA phenotypes, rather than disease stage, drive structural progression – identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2015;23(4):550–8.CrossRef

17.

Knoop J, van der Leeden M, Thorstensson CA, Roorda LD, Lems WF, Knol DL, et al. Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the Osteoarthritis Initiative. Arthritis Care Res. 2011;63(11):1535–42.CrossRef

18.

McGonagle D, Tan AL, Carey J, Benjamin M. The anatomical basis for a novel classification of osteoarthritis and allied disorders. J Anat. 2010;216(3):279–91.PubMedCentralCrossRefPubMed

19.

Van Spil WE, Jansen NWD, Bijlsma JWJ, Reijman M, DeGroot J, Welsing PMJ, et al. Clusters within a wide spectrum of biochemical markers for osteoarthritis: data from CHECK, a large cohort of individuals with very early symptomatic osteoarthritis. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2012;20(7):745–54.CrossRef

20.

Bay-Jensen AC, Slagboom E, Chen-An P, Alexandersen P, Qvist P, Christiansen C, et al. Role of hormones in cartilage and joint metabolism: understanding an unhealthy metabolic phenotype in osteoarthritis. Menopause N Y N. 2013;20(5):578–86.

21.

Bos SD, Beekman M, Maier AB, Karsdal MA, Kwok W-Y, Bay-Jensen AC, et al. Metabolic health in families enriched for longevity is associated with low prevalence of hand osteoarthritis and influences OA biomarker profiles. Ann Rheum Dis. 2013;72(10):1669–74.CrossRefPubMed

22.

Gandhi R, Razak F, Davey JR, Mahomed NN. Metabolic syndrome and the functional outcomes of hip and knee arthroplasty. J Rheumatol. 2010;37(9):1917–22.CrossRefPubMed

23.

Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol. 2012;8(12):729–37.CrossRefPubMed

24.

Gelber AC, Hochberg MC, Mead LA, Wang NY, Wigley FM, Klag MJ. Body mass index in young men and the risk of subsequent knee and hip osteoarthritis. Am J Med. 1999;107(6):542–8.CrossRefPubMed

25.

Gelber AC, Hochberg MC, Mead LA, Wang NY, Wigley FM, Klag MJ. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med. 2000;133(5):321–8.CrossRefPubMed

26.

Attur M, Belitskaya-Lévy I, Oh C, Krasnokutsky S, Greenberg J, Samuels J, et al. Increased interleukin-1β gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum. 2011;63(7):1908–17.PubMedCentralCrossRefPubMed

27.

Dolzani P, Assirelli E, Pulsatelli L, Addimanda O, Mancarella L, Peri G, et al. Systemic inflammation and antibodies to citrullinated peptides in hand osteoarthritis. Clin Exp Rheumatol. 2011;29(6):1006–9.PubMed

28.

Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop. 2004;(427 Suppl):S37–46.

29.

Scanzello CR, Umoh E, Pessler F, Diaz-Torne C, Miles T, Dicarlo E, et al. Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2009;17(8):1040–8.CrossRef

30.

Henriksen K, Karsdal MA, Martin TJ. Osteoclast-derived coupling factors in bone remodeling. Calcif Tissue Int. 2014;94(1):88–97.CrossRefPubMed

31.

Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within bone controls bone remodeling. Bone. 2009;44(6):1026–33.CrossRefPubMed

32.

Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthr Cartil OARS Osteoarthr Res Soc. 2008;16(6):638–46.CrossRef

33.

Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen A-C, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol. 2013;11(2):70–92.PubMedCentralCrossRefPubMed

34.

Attur M, Wang H-Y, Kraus VB, Bukowski JF, Aziz N, Krasnokutsky S, et al. Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations. Ann Rheum Dis. 2010;69(5):856–61.PubMedCentralCrossRefPubMed

35.

Dodd AW, Syddall CM, Loughlin J. A rare variant in the osteoarthritis-associated locus GDF5 is functional and reveals a site that can be manipulated to modulate GDF5 expression. Eur J Hum Genet EJHG. 2013;21(5):517–21.CrossRefPubMed

36.

Alexandersen P, Karsdal MA, Byrjalsen I, Christiansen C. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric J Int Menopause Soc. 2011;14(2):236–43.CrossRef

37.

Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Lau EM, Arnold M, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2010;18(2):150–9.CrossRef

38.

Reginster J-Y, Beaudart C, Neuprez A, Bruyère O. Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. Ther Adv Musculoskelet Dis. 2013;5(5):268–76.PubMedCentralCrossRefPubMed

39.

Reginster J-Y. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomised, placebo-controlled trial. Ann Rheum Dis. 2014;73(2):e8.CrossRefPubMed

40.

Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther. 2005;7(3):R625–33.PubMedCentralCrossRefPubMed

41.

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.CrossRef

42.

Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2011;19(5):515–42.CrossRef

43.

Lotz M, Martel-Pelletier J, Christiansen C, Brandi M-L, Bruyère O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72(11):1756–63.PubMedCentralCrossRefPubMed

44.

Van Spil WE, DeGroot J, Lems WF, Oostveen JCM, Lafeber FPJG. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2010;18(5):605–12.CrossRef

45.

Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthr Cartil OARS Osteoarthr Res Soc. 2006;14(8):723–7.CrossRef

46.

Jurisica I. Integrative cancer informatics for the identification of prognostic and predictive biomarkers. BMC Proc. 2013;7(Suppl 2 Sao Paulo Advanced School of Comparative Oncology: AbstractsClaudia Aparecida Rainho, Patricia Pintor dos Reis and Silvia Regina RogattoPublication of this supplement was funded by the Sao Paulo Research Foundation (FAPESP)):K7.

47.

Zhu C-Q, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(29):4417–24.CrossRef

48.

Frisenda S, Perricone C, Valesini G. Cartilage as a target of autoimmunity: a thin layer. Autoimmun Rev. 2013;12(5):591–8.CrossRefPubMed

49.

Nishioka K. Autoimmune response in cartilage-delivered peptides in a patient with osteoarthritis. Arthritis Res Ther. 2004;6(1):6–7.CrossRefPubMed

50.

Cooke TD. Significance of immune complex deposits in osteoarthritic cartilage. J Rheumatol. 1987;14 Spec No:77–9.

51.

Gandhi R, Tsvetkov D, Dhottar H, Davey JR, Mahomed NN. Quantifying the pain experience in hip and knee osteoarthritis. Pain Res Manag J Can Pain Soc J Société Can Pour Trait Douleur. 2010;15(4):224–8.

52.

Zhang W, Likhodii S, Zhang Y, Aref-Eshghi E, Harper PE, Randell E, et al. Classification of osteoarthritis phenotypes by metabolomics analysis. BMJ Open. 2014;4(11), e006286.PubMedCentralCrossRefPubMed

53.

Gaskell G, Gottweis H. Biobanks need publicity. Nature. 2011;471(7337):159–60.CrossRefPubMed

54.

Holzinger A, Dehmer M, Jurisica I. Knowledge discovery and interactive data mining in bioinformatics–state-of-the-art, future challenges and research directions. BMC Bioinformatics. 2014;15(Suppl 6):I1.

55.

Fortney K, Jurisica I. Integrative computational biology for cancer research. Hum Genet. 2011;130(4):465–81.PubMedCentralCrossRefPubMed

56.

Jurisica I. Mapping cancer markers – towards precision medicine [Internet]. http://www.cs.toronto.edu/~juris/MCM.htm. Cited 5 Apr 2015.

57.

Starmans MH, Pintilie M, John T, Der SD, Shepherd FA, Jurisica I, et al. Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Med. 2012;4(11):84.PubMedCentralCrossRefPubMed

58.

Pastrello C, Pasini E, Kotlyar M, Otasek D, Wong S, Sangrar W, et al. Integration, visualization and analysis of human interactome. Biochem Biophys Res Commun. 2014;445(4):757–73.CrossRefPubMed

59.

Mullard A. 23andMe sets sights on UK/Canada, signs up Genentech. Nat Biotechnol. 2015;33(2):119.CrossRefPubMed

60.

Yim S-H, Chung Y-J. Reflections on the US FDA’s warning on direct-to-consumer genetic testing. Genomics Inform. 2014;12(4):151–5.PubMedCentralCrossRefPubMed

61.

Slade Shantz JA, Veillette CJH. The application of wearable technology in surgery: ensuring the positive impact of the wearable revolution on surgical patients. Front Surg. 2014;1:39.PubMedCentralCrossRefPubMed

Medicine Matters Rheumatology

Abstract